Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 81
Filtrer
1.
Methods Mol Biol ; 2780: 15-26, 2024.
Article de Anglais | MEDLINE | ID: mdl-38987461

RÉSUMÉ

Protein-protein docking is considered one of the most important techniques supporting experimental proteomics. Recent developments in the field of computer science helped to improve this computational technique so that it better handles the complexity of protein nature. Sampling algorithms are responsible for the generation of numerous protein-protein ensembles. Unfortunately, a primary docking output comprises a set of both near-native poses and decoys. Application of the efficient scoring function helps to differentiate poses with the most favorable properties from those that are very unlikely to represent a natural state of the complex. This chapter explains the importance of sampling and scoring in the process of protein-protein docking. Moreover, it summarizes advances in the field.


Sujet(s)
Algorithmes , Simulation de docking moléculaire , Liaison aux protéines , Protéines , Simulation de docking moléculaire/méthodes , Protéines/composition chimique , Protéines/métabolisme , Biologie informatique/méthodes , Conformation des protéines , Cartographie d'interactions entre protéines/méthodes , Logiciel , Protéomique/méthodes
2.
ChemMedChem ; : e202400080, 2024 Apr 15.
Article de Anglais | MEDLINE | ID: mdl-38619283

RÉSUMÉ

The 5-HT2A receptor is a molecular target of high pharmacological importance. Ligands of this protein, particularly atypical antipsychotics, are useful in the treatment of numerous mental disorders, including schizophrenia and major depressive disorder. Structure-based virtual screening using a 5-HT2A receptor complex was performed to identify novel ligands for the 5-HT2A receptor, serving as potential antidepressants. From the Enamine screening library, containing over 4 million compounds, 48 molecules were selected for subsequent experimental validation. These compounds were tested against the 5-HT2A receptor in radioligand binding assays. From the tested batch, six molecules were identified as ligands of the main molecular target and were forwarded to a more detailed in vitro profiling. This included radioligand binding assays at 5-HT1A, 5-HT7, and D2 receptors and functional studies at 5-HT2A receptors. These compounds were confirmed to show a binding affinity for at least one of the targets tested in vitro. The success rate for the inactive template-based screening reached 17 %, while it was 9 % for the active template-based screening. Similarity and fragment analysis indicated the structural novelty of the identified compounds. Pharmacokinetics for these molecules was determined using in silico approaches.

3.
J Clin Med ; 13(6)2024 Mar 12.
Article de Anglais | MEDLINE | ID: mdl-38541849

RÉSUMÉ

Background: Dermatological conditions extend beyond physical symptoms, profoundly impacting the psychological well-being of patients. This study explores the intricate relationship between depressive symptoms, quality of life (QoL), and personality traits in individuals diagnosed with specific genodermatoses. Methods: The study cohort comprised 30 patients with genodermatoses treated at the dermatology clinic, and a healthy control group. Standardized survey questionnaires: The Dermatology Life Quality Index (DLQI), Beck's Depression Inventory (BDI), and NEO Five-Factor Inventory (NEO-FFI) were employed for assessments. Results: The findings indicate a significantly elevated risk of severely or very severely reduced QoL in the study group compared to matched controls (OR = 22.2, 95% CI: 2.7-184.8). Specifically, individuals with ichthyosis exhibited a staggering 131-fold higher risk of diminished QoL compared to the control group. Furthermore, the prevalence of depression was higher in the study group than in the control group (36.7% vs. 10%; p = 0.0086). A detailed analysis revealed that patients with low or average agreeableness exhibited a notably higher incidence of depression compared to those with high agreeableness (100% or 75% vs. 28.6%; p = 0.0400). Similarly, individuals with high levels of neuroticism had a significantly higher incidence of depression compared to those with average or low levels of neuroticism (rates: 66.7% vs. 9.1% or 0%, respectively; p = 0.0067). Conclusions: The study underscores a substantial correlation between genodermatoses and the mental health of affected individuals, underscoring the imperative consideration of psychological factors in the management of hereditary skin disorders. Our study's primary limitation is the small sample size, stemming from difficulties in recruiting participants due to the rare nature of the studied conditions.

4.
Molecules ; 29(3)2024 Jan 24.
Article de Anglais | MEDLINE | ID: mdl-38338317

RÉSUMÉ

µ-opioid receptor ligands such as morphine and fentanyl are the most known and potent painkillers. However, the severe side effects seen with their use significantly limit their widespread use. The continuous broadening of knowledge about the properties of the interactions of the MOP receptor (human mu opioid receptor, OP3) with ligands and specific intracellular signaling pathways allows for the designation of new directions of research with respect to compounds with analgesic effects in a mechanism different from classical ligands. Allosteric modulation is an extremely promising line of research. Compounds with modulator properties may provide a safer alternative to the currently used opioids. The aim of our research was to obtain a series of urea derivatives of 1-aryl-2-aminoimidazoline and to determine their activity, mechanism of biological action and selectivity toward the MOP receptor. The obtained compounds were subjected to functional tests (cAMP accumulation and ß-arrestin recruitment) in vitro. One of the obtained compounds, when administered alone, did not show any biological activity, while when co-administered with DAMGO, it inhibited ß-arrestin recruitment. These results indicate that this compound is a negative allosteric modulator (NAM) of the human MOP receptor.


Sujet(s)
Récepteur mu , Récepteurs aux opioïdes , Humains , Récepteurs aux opioïdes/métabolisme , Récepteur mu/métabolisme , Analgésiques morphiniques/effets indésirables , Analgésiques/pharmacologie , bêta-Arrestines/métabolisme
5.
Expert Opin Drug Discov ; 19(1): 73-83, 2024.
Article de Anglais | MEDLINE | ID: mdl-37807912

RÉSUMÉ

INTRODUCTION: Nowadays, it is widely accepted that water molecules play a key role in binding a ligand to a molecular target. Neglecting water molecules in the process of molecular recognition was the result of several failures of the structure-based drug discovery campaigns. The application of WaterMap, in particular WaterMap-guided molecular docking, enables the reasonably accurate and quick description of the location and energetics of water molecules at the ligand-protein interface. AREAS COVERED: In this review, the authors shortly discuss the importance of water in drug design and discovery and provide a brief overview of the computational approaches used to predict the solvent-related effects for the purposes of presenting WaterMap in the context of other available techniques and tools. A concise description of WaterMap concept is followed by the presentation of WaterMap-assisted virtual screening literature published between 2013 and 2023. EXPERT OPINION: In recent years, WaterMap software has been extensively used to support structure-based drug design, in particular structure-based virtual screening. Indeed, it is a useful tool to rescore docking results considering water molecules in the binding pocket. Although WaterMap allows for the consideration of the dynamic behavior of water molecules in the binding site, for best accuracy, its application in conjunction with other techniques such as molecular mechanics-generalized Born surface area of FEP (Free Energy Perturbation) is recommended.


Sujet(s)
Conception de médicament , Découverte de médicament , Humains , Simulation de docking moléculaire , Ligands , Découverte de médicament/méthodes , Sites de fixation , Eau/composition chimique
6.
Mol Neurobiol ; 61(7): 4834-4853, 2024 Jul.
Article de Anglais | MEDLINE | ID: mdl-38135855

RÉSUMÉ

With the aging of the population, treatment of conditions emerging in old age, such as neurodegenerative disorders, has become a major medical challenge. Of these, Alzheimer's disease, leading to cognitive dysfunction, is of particular interest. Neuronal loss plays an important role in the pathophysiology of this condition, and over the years, a great effort has been made to determine the role of various factors in this process. Unfortunately, until now, the exact pathomechanism of this condition remains unknown. However, the most popular theories associate AD with abnormalities in the Tau and ß-amyloid (Aß) proteins, which lead to their deposition and result in neuronal death. Neurons, like all cells, die in a variety of ways, among which pyroptosis, apoptosis, and necroptosis are associated with the activation of various caspases. It is worth mentioning that Tau and Aß proteins are considered to be one of the caspase activators, leading to cell death. Moreover, the protease activity of caspases influences both of the previously mentioned proteins, Tau and Aß, converting them into more toxic derivatives. Due to the variety of ways caspases impact the development of AD, drugs targeting caspases could potentially be useful in the treatment of this condition. Therefore, there is a constant need to search for novel caspase inhibitors and evaluate them in preclinical and clinical trials.


Sujet(s)
Maladie d'Alzheimer , Caspases , Maladie d'Alzheimer/traitement médicamenteux , Maladie d'Alzheimer/anatomopathologie , Maladie d'Alzheimer/enzymologie , Maladie d'Alzheimer/métabolisme , Humains , Caspases/métabolisme , Animaux , Protéines tau/métabolisme , Peptides bêta-amyloïdes/métabolisme , Activation enzymatique , Inhibiteurs des caspases/usage thérapeutique , Inhibiteurs des caspases/pharmacologie
7.
Biomolecules ; 13(10)2023 09 26.
Article de Anglais | MEDLINE | ID: mdl-37892131

RÉSUMÉ

Repeated maternal separation (MS) is a useful experimental model in rodents for studying the long-term influence of early-life stress on brain neurophysiology. In our work, we assessed the effect of repeated MS (postnatal day (PND)1-21, 180 min/day) on the postnatal development of rat brain regions involved in memory using proton magnetic resonance spectroscopy (1HMRS) for tissue volume and the level of amino acids such as glutamate, aspartate, glutamine, glycine and gamma-aminobutyric acid (GABA) in the hippocampus. We assessed whether these effects are sex dependent. We also use novel object recognition (NOR) task to examine the effect of MS on memory and the effect of ethanol on it. Finally, we attempted to ameliorate postnatal stress-induced memory deficits by using VU-29, a positive allosteric modulator (PAM) of the metabotropic glutamate type 5 (mGlu5) receptor. In males, we noted deficits in the levels of glutamate, glycine and glutamine and increases in GABA in the hippocampus. In addition, the values of perirhinal cortex, prefrontal cortex and insular cortex and CA3 were decreased in these animals. MS females, in contrast, demonstrated significant increase in glutamate levels and decrease in GABA levels in the hippocampus. Here, the CA1 values alone were increased. VU-29 administration ameliorated these cognitive deficits. Thus, MS stress disturbs amino acids levels mainly in the hippocampus of adult male rats, and enhancement of glutamate neurotransmission reversed recognition memory deficits in these animals.


Sujet(s)
Acides aminés , Dysfonctionnement cognitif , Femelle , Rats , Mâle , Animaux , Acides aminés/métabolisme , Glutamine/métabolisme , Caractères sexuels , Séparation d'avec la mère , Encéphale/métabolisme , Dysfonctionnement cognitif/métabolisme , Acide glutamique/métabolisme , Acide gamma-amino-butyrique/métabolisme , Troubles de la mémoire , Récepteur-5 métabotropique du glutamate/métabolisme , Hippocampe/métabolisme , Glycine/métabolisme
8.
Cells ; 12(7)2023 04 03.
Article de Anglais | MEDLINE | ID: mdl-37048149

RÉSUMÉ

Cosmetic products contain preservatives to prevent microbial growth. The various types of preservatives present in skincare products applied on the skin induce many side effects. We tested several types of preservatives such as phenoxyethanol, methyl paraben, propyl paraben, imidazolidinyl urea (IU), the composition of gluconolactone and sodium benzoate (GSB), diazolidinyl urea (DU), and two grapefruit essential oils, one of which was industrially produced and a second which was freshly distilled from fresh grapefruit peels. This study aimed to find the relationship between preservative concentration, cell growth, collagen secretion, and cell viability. We hypothesized that these products induced a decrease in collagen secretion from human dermal fibroblasts. Our research, for the first time, addressed the overall effect of other preservatives on skin extracellular matrix (ECM) by studying their effect on metalloproteinase-2 (MMP-2) activity. Except for cytotoxicity and contact sensitivity tests, there are no studies of their effect on skin ECM in the available literature. These studies show potential antimicrobial activity, especially from the compounds IU and DU towards reference bacteria and the compounds methyl paraben and propyl paraben against reference fungi. The MTS test showed that fibroblasts are more sensitive to the tested group of preservatives than keratinocytes, which could be caused by the differences between the cells' structures. The grapefruit oils exhibited the most cytotoxicity to both tested cell lines compared to all considered preservatives. The most destructive influence of preservatives on collagen synthesis was observed in the case of IU and DU. In this case, the homemade grapefruit oil turned out to be the mildest one. The results from a diverse group of preservatives show that whether they are natural or synthesized compounds, they require controlled use. Appropriate dosages and evaluation of preservative efficacy should not be the only aspects considered. The complex effect of preservatives on skin processes and cytotoxicity is an important topic for modern people.


Sujet(s)
Cosmétiques , Parabènes , Humains , Matrix metalloproteinase 2 , Conservateurs pharmaceutiques/effets indésirables , Cosmétiques/pharmacologie , Cosmétiques/composition chimique , Allergènes
9.
Methods Mol Biol ; 2627: 25-40, 2023.
Article de Anglais | MEDLINE | ID: mdl-36959440

RÉSUMÉ

Homology modeling was long considered a method of choice in tertiary protein structure prediction. However, it used to provide models of acceptable quality only when templates with appreciable sequence identity with a target could be found. The threshold value was long assumed to be around 20-30%. Below this level, obtained sequence identity was getting dangerously close to values that can be obtained by chance, after aligning any random, unrelated sequences. In these cases, other approaches, including ab initio folding simulations or fragment assembly, were usually employed. The most recent editions of the CASP and CAMEO community-wide modeling methods assessment have brought some surprising outcomes, proving that much more clues can be inferred from protein sequence analyses than previously thought. In this chapter, we focus on recent advances in the field of difficult protein modeling, pushing the threshold deep into the "twilight zone", with particular attention devoted to improvements in applications of machine learning and model evaluation.


Sujet(s)
Apprentissage machine , Protéines , Protéines/composition chimique , Structure tertiaire des protéines , Analyse de séquence de protéine/méthodes , Conformation des protéines , Pliage des protéines , Bases de données de protéines , Biologie informatique/méthodes
10.
Int J Mol Sci ; 24(3)2023 Feb 02.
Article de Anglais | MEDLINE | ID: mdl-36769269

RÉSUMÉ

Complex disorders, such as depression, remain a mystery for scientists. Although genetic factors are considered important for the prediction of one's vulnerability, it is hard to estimate the exact risk for a patient to develop depression, based only on one category of vulnerability criteria. Genetic factors also regulate drug metabolism, and when they are identified in a specific combination, may result in increased drug resistance. A proper understanding of the genetic basis of depression assists in the development of novel promising medications and effective disorder management schemes. This review aims to analyze the recent literature focusing on the correlation between specific genes and the occurrence of depression. Moreover, certain aspects targeting a high drug resistance identified among patients suffering from major depressive disorder were highlighted in this manuscript. An expected direction of future drug discovery campaigns was also discussed.


Sujet(s)
Trouble dépressif majeur , Humains , Trouble dépressif majeur/traitement médicamenteux , Trouble dépressif majeur/génétique , Dépression/traitement médicamenteux , Dépression/génétique , Résistance aux substances
11.
Molecules ; 27(9)2022 May 04.
Article de Anglais | MEDLINE | ID: mdl-35566280

RÉSUMÉ

The µ-opioid receptors belong to the family of G protein-coupled receptors (GPCRs), and their activation triggers a cascade of intracellular relays with the final effect of analgesia. Classical agonists of this receptor, such as morphine, are the main targets in the treatment of both acute and chronic pain. However, the dangerous side effects, such as respiratory depression or addiction, significantly limit their widespread use. The allosteric centers of the receptors exhibit large structural diversity within particular types and even subtypes. Currently, a considerable interest is aroused by the modulation of µ-opioid receptors. The application of such a technique may result in a reduction in the dose or even discontinuation of classical opiates, thus eliminating the side effects typical of this class of drugs. Our aim is to obtain a series of 1-aryl-5,6(1H)dioxo-2,3-dihydroimidazo[1,2-a]imidazole derivatives and provide more information about their activity and selectivity on OP3 (MOP, human mu opioid receptor). The study was based on an observation that some carbonyl derivatives of 1-aryl-2-aminoimidazoline cooperate strongly with morphine or DAMGO in sub-threshold doses, producing similar results to those of normal active doses. To elucidate the possible mechanism of such enhancement, we performed a few in vitro functional tests (involving cAMP and ß-arrestin recruitment) and a radioligand binding assay on CHO-K1 cells with the expression of the OP3 receptor. One of the compounds had no orthosteric affinity or intrinsic activity, but inhibited the efficiency of DAMGO. These results allow to conclude that this compound is a negative allosteric modulator (NAM) of the human µ-opioid receptor.


Sujet(s)
Morphine , Récepteur mu , Analgésiques morphiniques/usage thérapeutique , Animaux , Cricetinae , Cricetulus , 2-Alanine-5-glycine-4-méthylphénylalanine-enképhaline , Humains , Imidazoles/pharmacologie , Morphine/pharmacologie , Récepteur mu/métabolisme
12.
Expert Opin Drug Discov ; 17(7): 673-683, 2022 07.
Article de Anglais | MEDLINE | ID: mdl-35549603

RÉSUMÉ

INTRODUCTION: Current findings on multifactorial diseases with a complex pathomechanism confirm that multi-target drugs are more efficient ways in treating them as opposed to single-target drugs. However, to design multi-target ligands, a number of factors and challenges must be taken into account. AREAS COVERED: In this perspective, we summarize the concept of application of multi-target drugs for the treatment of complex diseases such as neurodegenerative diseases, schizophrenia, diabetes, and cancer. We discuss the aspects of target selection for multifunctional ligands and the application of in silico methods in their design and optimization. Furthermore, we highlight other challenges such as balancing affinities to different targets and drug-likeness of obtained compounds. Finally, we present success stories in the design of multi-target ligands for the treatment of common complex diseases. EXPERT OPINION: Despite numerous challenges resulting from the design of multi-target ligands, these efforts are worth making. Appropriate target selection, activity balancing, and ligand drug-likeness belong to key aspects in the design of ligands acting on multiple targets. It should be emphasized that in silico methods, in particular inverse docking, pharmacophore modeling, machine learning methods and approaches derived from network pharmacology are valuable tools for the design of multi-target drugs.


Sujet(s)
Maladies neurodégénératives , Schizophrénie , Conception de médicament , Humains , Ligands , Maladies neurodégénératives/traitement médicamenteux , Schizophrénie/traitement médicamenteux
13.
Molecules ; 27(8)2022 Apr 12.
Article de Anglais | MEDLINE | ID: mdl-35458681

RÉSUMÉ

The blockade of kainate receptors, in particular with non-competitive antagonists, has-due to their anticonvulsant and neuroprotective properties-therapeutic potential in many central nervous system (CNS) diseases. Deciphering the structural properties of kainate receptor ligands is crucial to designing medicinal compounds that better fit the receptor binding pockets. In light of that fact, here, we report experimental and computational structural studies of four indole derivatives that are non-competitive antagonists of GluK1/GluK2 receptors. We used X-ray studies and Hirshfeld surface analysis to determine the structure of the compounds in the solid state and quantum chemical calculations to compute HOMO and LUMO orbitals and the electrostatic potential. Moreover, non-covalent interaction maps were also calculated. It is worth emphasizing that compounds 3 and 4 are achiral molecules crystallising in non-centrosymmetric space groups, which is a relatively rare phenomenon.


Sujet(s)
Indoles , Récepteurs kaïnate , Indoles/pharmacologie , Ligands , Liaison aux protéines , Récepteurs kaïnate/composition chimique , Récepteurs kaïnate/métabolisme
14.
Pharmacol Rep ; 74(2): 406-424, 2022 Apr.
Article de Anglais | MEDLINE | ID: mdl-35064921

RÉSUMÉ

BACKGROUND: Allosteric modulation of G protein-coupled receptors (GPCRs) is nowadays one of the hot topics in drug discovery. In particular, allosteric modulators of D2 receptor have been proposed as potential modern therapeutics to treat schizophrenia and Parkinson's disease. METHODS: To address some subtle structural and stereochemical aspects of allosteric modulation of D2 receptor, we performed extensive in silico studies of both enantiomers of two compounds (compound 1 and compound 2), and one of them (compound 2) was synthesized as a racemate in-house and studied in vitro. RESULTS: Our molecular dynamics simulations confirmed literature reports that the R enantiomer of compound 1 is a positive allosteric modulator of the D2L receptor, while its S enantiomer is a negative allosteric modulator. Moreover, based on the principal component analysis (PCA), we hypothesized that both enantiomers of compound 2 behave as silent allosteric modulators, in line with our in vitro studies. PCA calculations suggest that the most pronounced modulator-induced receptor rearrangements occur at the transmembrane helix 7 (TM7). In particular, TM7 bending at the conserved P7.50 and G7.42 was observed. The latter resides next to the Y7.43, which is a significant part of the orthosteric binding site. Moreover, the W7.40 conformation seems to be affected by the presence of the positive allosteric modulator. CONCLUSIONS: Our work reveals that allosteric modulation of the D2L receptor can be affected by subtle ligand modifications. A change in configuration of a chiral carbon and/or minor structural modulator modifications are solely responsible for the functional outcome of the allosteric modulator.


Sujet(s)
Dopamine , Simulation de dynamique moléculaire , Régulation allostérique , Sites de fixation , Ligands , Récepteurs couplés aux protéines G
15.
Biomolecules ; 11(6)2021 06 16.
Article de Anglais | MEDLINE | ID: mdl-34208760

RÉSUMÉ

Parkinson's disease is a progressive neurodegenerative disorder characterized by the death of nerve cells in the substantia nigra of the brain. The treatment options for this disease are very limited as currently the treatment is mainly symptomatic, and the available drugs are not able to completely stop the progression of the disease but only to slow it down. There is still a need to search for new compounds with the most optimal pharmacological profile that would stop the rapidly progressing disease. An increasing understanding of Parkinson's pathogenesis and the discovery of new molecular targets pave the way to develop new therapeutic agents. The use and selection of appropriate cell and animal models that better reflect pathogenic changes in the brain is a key aspect of the research. In addition, computer-assisted drug design methods are a promising approach to developing effective compounds with potential therapeutic effects. In light of the above, in this review, we present current approaches for developing new drugs for Parkinson's disease.


Sujet(s)
Développement de médicament/méthodes , Développement de médicament/tendances , Maladie de Parkinson/traitement médicamenteux , Animaux , Encéphale/anatomopathologie , Humains , Neurones/anatomopathologie , Neuroprotecteurs/usage thérapeutique , Maladie de Parkinson/anatomopathologie , Substantia nigra/anatomopathologie
16.
Int J Mol Sci ; 23(1)2021 Dec 21.
Article de Anglais | MEDLINE | ID: mdl-35008436

RÉSUMÉ

Depression is a multifactorial disorder that affects millions of people worldwide, and none of the currently available therapeutics can completely cure it. Thus, there is a need for developing novel, potent, and safer agents. Recent medicinal chemistry findings on the structure and function of the serotonin 2A (5-HT2A) receptor facilitated design and discovery of novel compounds with antidepressant action. Eligible papers highlighting the importance of 5-HT2A receptors in the pathomechanism of the disorder were identified in the content-screening performed on the popular databases (PubMed, Google Scholar). Articles were critically assessed based on their titles and abstracts. The most accurate papers were chosen to be read and presented in the manuscript. The review summarizes current knowledge on the applicability of 5-HT2A receptor signaling modulators in the treatment of depression. It provides an insight into the structural and physiological features of this receptor. Moreover, it presents an overview of recently conducted virtual screening campaigns aiming to identify novel, potent 5-HT2A receptor ligands and additional data on currently synthesized ligands acting through this protein.


Sujet(s)
Antidépresseurs/composition chimique , Dépression/métabolisme , Récepteur de la sérotonine de type 5-HT2A/composition chimique , Récepteur de la sérotonine de type 5-HT2A/métabolisme , Antidépresseurs/pharmacologie , Antidépresseurs/usage thérapeutique , Dépression/traitement médicamenteux , Conception de médicament , Humains , Ligands , Modèles moléculaires , Conformation des protéines , Agonistes des récepteurs 5-HT2 de la sérotonine/composition chimique , Agonistes des récepteurs 5-HT2 de la sérotonine/pharmacologie , Agonistes des récepteurs 5-HT2 de la sérotonine/usage thérapeutique , Antagonistes des récepteurs 5-HT2 de la sérotonine/composition chimique , Antagonistes des récepteurs 5-HT2 de la sérotonine/pharmacologie , Antagonistes des récepteurs 5-HT2 de la sérotonine/usage thérapeutique , Relation structure-activité
17.
Int J Mol Sci ; 21(22)2020 Nov 23.
Article de Anglais | MEDLINE | ID: mdl-33238370

RÉSUMÉ

The treatment of memory impairments associated with the central nervous system diseases remains an unmet medical need with social and economic implications. Here we show, that a multi-target ligand of aminergic G protein-coupled receptors with antipsychotic activity in vivo (D2AAK1) stimulates neuron growth and survival and promotes neuron integrity. We focused on the multilevel evaluation of the D2AAK1-related effects on neurons in terms of behavioral, cellular, molecular, and biochemical features in vivo and in vitro, such as memory-related responses, locomotor activity, tissue sections analysis, metabolic activity, proliferation level, neurons morphology, and proteins level involved in intracellular signaling pathways. In silico studies indicate that activation of calcium/calmodulin-dependent protein kinase I (CaMKI) may underline some of the observed activities of the compound. Furthermore, the compound increases hippocampal neuron proliferation via the activation of neurotrophic factors and cooperating signals responsible for cell growth and proliferation. D2AAK1 improves memory and learning processes in mice after both acute and chronic administration. D2AAK1 also causes an increase in the number of hippocampal pyramidal neurons after chronic administration. Because of its neuroprotective properties and pro-cognitive activity in behavioral studies D2AAK1 has the potential for the treatment of memory disturbances in neurodegenerative and mental diseases.


Sujet(s)
Neuroleptiques/pharmacologie , Indoles/pharmacologie , Mémoire/effets des médicaments et des substances chimiques , Troubles mentaux/traitement médicamenteux , Maladies neurodégénératives/traitement médicamenteux , Pyrrolidines/pharmacologie , Animaux , Modèles animaux de maladie humaine , Hippocampe/effets des médicaments et des substances chimiques , Hippocampe/physiopathologie , Apprentissage/effets des médicaments et des substances chimiques , Locomotion/effets des médicaments et des substances chimiques , Troubles de la mémoire/traitement médicamenteux , Troubles de la mémoire/physiopathologie , Troubles mentaux/physiopathologie , Souris , Maladies neurodégénératives/physiopathologie , Phosphorylation/effets des médicaments et des substances chimiques , Cellules pyramidales/effets des médicaments et des substances chimiques , Cellules pyramidales/anatomopathologie , Transduction du signal/effets des médicaments et des substances chimiques
18.
Int J Mol Sci ; 21(22)2020 Nov 11.
Article de Anglais | MEDLINE | ID: mdl-33187107

RÉSUMÉ

Opioids are the drugs of choice in severe pain management. Unfortunately, their use involves serious, potentially lethal side effects. Therefore, efforts in opioid drug design turn toward safer and more effective mechanisms, including allosteric modulation. In this study, molecular dynamics simulations in silico and 'writhing' tests in vivo were used to characterize potential allosteric mechanism of two previously reported compounds. The results suggest that investigated compounds bind to µ opioid receptor in an allosteric site, augmenting action of morphine at subeffective doses, and exerting antinociceptive effect alone at higher doses. Detailed analysis of in silico calculations suggests that first of the compounds behaves more like allosteric agonist, while the second compound acts mainly as a positive allosteric modulator.


Sujet(s)
Régulation allostérique/physiologie , Site allostérique/physiologie , Récepteur mu/métabolisme , Régulation allostérique/effets des médicaments et des substances chimiques , Site allostérique/effets des médicaments et des substances chimiques , Analgésiques/pharmacologie , Analgésiques morphiniques/pharmacologie , Animaux , Simulation numérique , Mâle , Souris , Simulation de dynamique moléculaire , Morphine/pharmacologie , Douleur/traitement médicamenteux , Douleur/métabolisme
19.
Curr Top Med Chem ; 20(31): 2852-2865, 2020.
Article de Anglais | MEDLINE | ID: mdl-32479245

RÉSUMÉ

Opioid signaling plays a central role in pain perception. As such, it remains the main target in the development of antinociceptive agents, despite serious side effects involved. In recent years, hopes for improved opioid painkillers are rising, together with our understanding of allosterism and biased signaling mechanisms. In this review, we focus on recently discovered allosteric modulators of opioid receptors, insights into phenomena underlying their action, as well as on how they extend our understanding of mechanisms of previously known compounds. A brief overlook of their synthesis is also presented.


Sujet(s)
Analgésiques morphiniques/pharmacologie , Douleur/traitement médicamenteux , Récepteurs aux opioïdes/métabolisme , Régulation allostérique/effets des médicaments et des substances chimiques , Site allostérique/effets des médicaments et des substances chimiques , Analgésiques morphiniques/synthèse chimique , Analgésiques morphiniques/composition chimique , Humains , Douleur/métabolisme
20.
Biomolecules ; 10(5)2020 05 20.
Article de Anglais | MEDLINE | ID: mdl-32443872

RÉSUMÉ

: Metabotropic glutamate subtype 5 (mGlu5) receptors are implicated in various forms of synaptic plasticity, including drugs of abuse. In drug-addicted individuals, associative memories can drive relapse to drug use. The present study investigated the potential of the mGlu5 receptor positive allosteric modulator (PAM), VU-29 (30 mg/kg, i.p.), to inhibit the maintenance of a learned association between ethanol and environmental context by using conditioned place preference (CPP) in rats. The ethanol-CPP was established by the administration of ethanol (1.0 g/kg, i.p. × 10 days) using an unbiased procedure. Following ethanol conditioning, VU-29 was administered at various post-conditioning times (ethanol free state at the home cage) to ascertain if there was a temporal window during which VU-29 would be effective. Our experiments indicated that VU-29 did not affect the expression of ethanol-induced CPP when it was given over two post-conditioning days. However, the expression of ethanol-CPP was inhibited by 10-day home cage administration of VU-29, but not by first 2-day or last 2-day injection of VU-29 during the 10-day period. These findings reveal that VU-29 can inhibit the maintenance of ethanol-induced CPP, and that treatment duration contributes to this effect of VU-29. Furthermore, VU-29 effect was reversed by pretreatment with either MTEP (the mGlu5 receptor antagonist), or MK-801 (the N-methyl-D-aspartate-NMDA receptor antagonist). Thus, the inhibitory effect of VU-29 is dependent on the functional interaction between mGlu5 and NMDA receptors. Because a reduction in ethanol-associated cues can reduce relapse, mGlu5 receptor PAM would be useful for therapy of alcoholism. Future research is required to confirm the current findings.


Sujet(s)
Alcoolisme/traitement médicamenteux , Benzamides/usage thérapeutique , Pyrazoles/usage thérapeutique , Récepteur-5 métabotropique du glutamate/métabolisme , Régulation allostérique , Animaux , Benzamides/pharmacologie , Signaux , Mâle , Pyrazoles/pharmacologie , Rats , Rat Wistar , Récepteur-5 métabotropique du glutamate/agonistes , Récompense
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...